Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1785279 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.22Day +0.83%Mkt cap $46M1Y −46.3%Off 52W high −69.1%Vol (1Y) 66.5%
Daily closing price, split-adjusted to the current basis; 2.4y shown of 613 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest4.1% of sh out |
| Days to cover6.5d |
| 13F net flow (QoQ)−0.86% |
| Top-10 13F concentration77.6% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$22.3M |
| Earnings (TTM)-$85.9M |
| ROE−44.7% |
| Net margin−348.5% |
| ROIC−46.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−24.7% |
| 1Y−46.3% |
| Since incept. (ann.)−57.9% |
Total return through 2026-07-30 · series begins 2024-02-09. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)66.5% |
| Ann. volatility (3Y)112.5% |
| Sharpe (1Y)−0.68 |
| Sharpe (3Y)−0.34 |
| Max drawdown (1Y)−66.0% |
| Max drawdown (3Y)−90.7% |
| Beta (3Y vs SPY)0.62 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $1M | 2.81% | new |
| RENAISSANCE TECHNOLOGIES LLC | 787,900 | $1M | 2.09% | +25.4% |
| Catalio Capital Management, LP | 528,993 | $708,851 | 1.41% | +0.0% |
| Peapod Lane Capital LLC | 516,761 | $682,915 | 1.37% | +3.8% |
| TWO SIGMA INVESTMENTS, LP | 496,767 | $665,668 | 1.32% | +12.5% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 395,800 | $530,372 | 1.05% | +0.0% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 382,153 | $512,085 | 1.02% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 358,200 | $480,157 | 0.95% | +17.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.61 | — | $1.2M | −69.8% |
| 2025-12-31 | 2026-03-05 | — | — | $3.9M | −59.3% |
| 2025-09-30 | 2025-11-12 | −$0.55 | — | $8.7M | −24.8% |
| 2025-06-30 | 2025-08-12 | −$0.54 | — | $8.5M | −57.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
